Ipilimumab in the treatment of metastatic melanoma: management of adverse events

Giuseppina Della Vittoria Scarpati,; Celeste, Fusciello; Francesco Francesco Perri,; Francesco, Sabbatino; Chiara, Carlomagno; Pepe, Stefano; Soldano, Ferrone

doi:10.2147/OTT.S57335

UniSa - IRIS Institutional Research Information System

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

Recently, "ipilimumab," an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. "CTLA-4" is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targeting CTLA-4, is able to remove the CTLA-4 inhibitory signal, allowing the immune system to react to cancer cells. Due to its immune-based mechanism of action, ipilimumab causes the inhibition of CTLA-4-mediated immunomodulatory effects, the enhancement of antitumor specific immune response mediated by the weakening of self-tolerance mechanisms while exacerbating the development of autoimmune diseases and immune-related adverse events, including dermatitis, hepatitis, enterocolitis, hypophysitis, and uveitis.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11386/4583486

Titolo:	Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Autori:	Giuseppina Della Vittoria Scarpati Celeste Fusciello Francesco Francesco Perri Francesco Sabbatino Chiara Carlomagno PEPE, Stefano Soldano Ferrone mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2014
Rivista:	ONCOTARGETS AND THERAPY
Abstract:	Recently, "ipilimumab," an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. "CTLA-4" is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targeting CTLA-4, is able to remove the CTLA-4 inhibitory signal, allowing the immune system to react to cancer cells. Due to its immune-based mechanism of action, ipilimumab causes the inhibition of CTLA-4-mediated immunomodulatory effects, the enhancement of antitumor specific immune response mediated by the weakening of self-tolerance mechanisms while exacerbating the development of autoimmune diseases and immune-related adverse events, including dermatitis, hepatitis, enterocolitis, hypophysitis, and uveitis.
Handle:	http://hdl.handle.net/11386/4583486
Appare nelle tipologie:	1.1.2 Articolo su rivista con ISSN

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.